Communiqués Viking Therapeutics, Inc.

Actions

VKTX

US92686J1060

Recherche biotechnologique et médicale

Marché Fermé - Nasdaq 22:00:00 08/09/2026			Varia. 5j.	Varia. 1 janv.
33,68 ^USD	-3,41%		+0,03%	-4,26%

03/08	Viking Therapeutics : le VK2735 offre de multiples perspectives de croissance, selon Oppenheimer	MT
30/07	Les traitements de Viking contre l'obésité progressent alors que de nouvelles données et essais se profilent, selon Oppenheimer	MT

Communiqués

03/09	Viking Therapeutics to Participate at Upcoming Investor Conferences	AQ
30/07	Viking Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update	AQ
23/07	Viking Therapeutics to Report Financial Results for Second Quarter 2026 on July 29, 2026	AQ
30/04	Viking Therapeutics : May 2026 Corporate Presentation	PU
13/04	Viking Therapeutics to Participate at Upcoming Investor Conferences	AQ
13/03	Viking Therapeutics : March 2026 Corporate Presentation	PU
05/03	Viking Therapeutics : to Participate at Upcoming Investor Conferences	PU
12/02	Viking Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Provides Corporate Update	AQ
04/02	Viking Therapeutics : to Report Financial Results for Fourth Quarter and Year-End 2025 on February 11, 2026	PU
12/01	Viking Therapeutics : Announces Publication of Results from Phase 2 VENTURE Trial of Dual GLP-1/GIP Receptor Agonist VK2735 in the Journal Obesity	PU
06/01	Viking Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference	AQ
26/11	Viking Therapeutics to Participate at the Piper Sandler 37th Annual Healthcare Conference	AQ
20/11	Viking Therapeutics Announces Completion of Enrollment in Phase 3 VANQUISH-1 Trial of VK2735	AQ
19/11	Viking Therapeutics : November 2025 Corporate Presentation	PU
01/10/25	Viking Therapeutics : October 2025 Corporate Presentation	PU
24/09/25	Viking Therapeutics : September 2025 Corporate Presentation	PU
28/08/25	Viking Therapeutics to Participate at Upcoming Investor Conferences	PR
19/08/25	Viking Therapeutics Announces Positive Top-Line Results from Phase 2 VENTURE-Oral Dosing Trial of VK2735 Tablet Formulation in Patients with Obesity	PR
18/08/25	Profusa Inc (NASDAQ: PFSA) Establishes a distributor partner in Spain for Lumee Oxygen platform	AQ
23/07/25	Viking Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update	PR
16/07/25	Viking Therapeutics to Report Financial Results for Second Quarter 2025 on July 23, 2025	PR
03/07/25	Viking Therapeutics : July 2025 Corporate Presentation	PU
25/06/25	Viking Therapeutics Announces Initiation of Phase 3 Obesity Clinical Program with GLP-1/GIP Agonist VK2735	PR
14/06/25	Viking Therapeutics : June 2025 Corporate Presentation	PU
16/04/25	Viking Therapeutics to Report Financial Results for First Quarter 2025 on April 23, 2025	PR